As of 2024-12-15, the Relative Valuation of Maat Pharma SA (MAAT.PA) is (21.76) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 8.06 EUR, the upside of Maat Pharma SA based on Relative Valuation is -370.0%.
The range of the Relative Valuation is (16.92) - (26.60) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 9.8x - 15.3x | 12.6x |
| Forward P/E multiples | 9.8x - 15.3x | 12.6x |
| Fair Price | (16.92) - (26.60) | (21.76) |
| Upside | -310.0% - -430.0% | -370.0% |
| Date | P/E |
| 2024-11-20 | -4.75 |
| 2024-11-19 | -4.79 |
| 2024-11-18 | -4.71 |
| 2024-11-15 | -4.35 |
| 2024-11-14 | -4.38 |
| 2024-11-13 | -4.34 |
| 2024-11-12 | -4.49 |
| 2024-11-11 | -4.53 |
| 2024-11-08 | -4.50 |
| 2024-11-07 | -4.42 |
| 2024-11-06 | -4.31 |
| 2024-11-05 | -4.24 |
| 2024-11-04 | -4.23 |
| 2024-11-01 | -4.15 |
| 2024-10-31 | -4.23 |
| 2024-10-30 | -4.27 |
| 2024-10-29 | -4.27 |
| 2024-10-28 | -4.29 |
| 2024-10-25 | -4.13 |
| 2024-10-24 | -4.13 |
| 2024-10-23 | -4.01 |
| 2024-10-22 | -4.09 |
| 2024-10-21 | -4.20 |
| 2024-10-18 | -4.23 |
| 2024-10-17 | -4.18 |
| 2024-10-16 | -4.15 |
| 2024-10-15 | -4.29 |
| 2024-10-14 | -4.21 |
| 2024-10-11 | -4.15 |
| 2024-10-10 | -4.14 |
| 2024-10-09 | -4.24 |
| 2024-10-08 | -4.24 |
| 2024-10-07 | -4.27 |
| 2024-10-04 | -4.23 |
| 2024-10-03 | -4.24 |
| 2024-10-02 | -4.27 |
| 2024-10-01 | -4.22 |
| 2024-09-30 | -4.28 |
| 2024-09-27 | -4.28 |
| 2024-09-26 | -4.30 |
| 2024-09-25 | -4.28 |
| 2024-09-24 | -4.20 |
| 2024-09-23 | -4.22 |
| 2024-09-20 | -4.23 |
| 2024-09-19 | -4.21 |
| 2024-09-18 | -4.12 |
| 2024-09-17 | -4.21 |
| 2024-09-16 | -4.15 |
| 2024-09-13 | -4.19 |
| 2024-09-12 | -4.18 |